Search results :

Gemcitabine

More information: STITCH, PubChem (stereo-specific compound: 1) and possibly Wikipedia

ATC Code: L01BC05

Side effects

Options: Show MedDRA Preferred Terms,   display all 27 labels

Side effect Data for drug Placebo Labels
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Oedema peripheral very common, 20% x x x x x x x x x x x x x x x x x x x x
Malaise 19% x x x x x x x x x x x x x x x x x x x
Neutropenia very common, 0% - 89% x x x x x x x x x x x x x x x x x x x
Shivering very common x x
Influenza-like symptoms very common x x x x x x x x x x x x x x x x x x x
Cutaneous hypersensitivity very common x x
Oedema very rare — 13% x x x x x x x x x x x x x x x x x x x x
Lymphopenia 5% - 51% x x x x x
Asthenia common, very common x x x x x x x x x x x x x x x x x x x x
Back pain common, very common x x x
Pruritus common, very common x x x x x x x x x x x
Vomiting very common, 0% - 86% x x x x x x x x x x x x x x x x x x x x
Anaemia very common, 0% - 86% x x x x x x x x x x x x x x x x x x x x
Leukopenia very common, 0% - 93% x x x x x x x x x x x x x x x
Nausea very common, 0% - 87% x x x x x x x x x x x x x x x x x x x x
Ulcer rare, common x x x
Blood bilirubin increased common x x x
Insomnia common x x x x x x x x x x x x x x x x x x
Thrombocytopenia postmarketing — 1% - 57% x x x x x x x x
Alanine aminotransferase increased 0% - 68% x x x x x x
Aspartate aminotransferase increased 0% - 67% x x x x x x
Febrile neutropenia common, 0% - 5% x x x x
Constipation common, 0% - 39% x x x x x x x x x x x x x x x x x x x x
Dyspnoea very common, 0% - 28% x x x x x x x x x x x x x x x x x x x x
Hyperglycaemia 0% - 23% x x x x x x x x x x x x x x x
Neuropathy peripheral 3% x x x
Myalgia very common, 0% - 33% x x x x x x x x x x x x x x x x x x x
Arthralgia 0% - 22% x x x x x x x x x
Infection 0% - 47% x x x x x x x x x x x x x x x x x x x
Hyperbilirubinaemia 1% - 13% x x x x x
Creatinine increased 0% - 31% x x x x x x
Hypomagnesaemia 0% - 17% x x x x x x x x x x x x x x x x
Phosphatase alkaline increased 0% - 55% x x x x x x
Neuropathy 0% - 58% x x x x x
Fatigue 0% - 32% x x x x x x x x x x x x x x x x
Diarrhoea common, 0% - 34% x x x x x x x x x x x x x x x x x x x x
Hypotension rare, 0% - 7% x x x x x x x x x x x x x x x x x x
Transaminases increased 0% - 10% x x x x
Allergic bronchospasm 2% x x x x x x x x x x
Bronchospasm uncommon x x x x x x x x x x x x x x x x x x x
Cerebrovascular accident uncommon x x x x x x x x x x x x x x
Alopecia common, 0% - 92% x x x x x x x x x x x x x x x x x x x x
Haemorrhage 0% - 23% x x x x x x x x x x x x x x x x x x x x
Hypocalcaemia 0% - 7% x x x x x x x x x x x x x x x
Pain 1% x x x x x x x x x x x x
Paraesthesia 0% - 26% x x x x x x x x x x x x x x x x x
Pharyngitis 0% - 13% x x x x x x x x x x x x x x
Stomatitis common, 0% - 66% x x x x x x x x x x x x x x x x x x x x
Generalised oedema 1% x x x x x x x x x x x x x
Sepsis 1% x x x x x x x x x x x x x x x x
Face oedema 1% x x x
Somnolence common, 0% - 30% x x x x x x x x x x x x x x x x x x x
Arrhythmia postmarketing, rare x x x x x x x x x x x x x x x x x x x x
Neoplasm malignant postmarketing x x x x x
Cellulitis postmarketing x x x x x x x x x x x x
Extravasation postmarketing x x x x x x x x x x x x x x x x x
Gangrene very rare, postmarketing x x x x x x x x x x x x x x x x x
Cardiac failure postmarketing, rare x x x x x x
Cardiac failure congestive postmarketing x x x x x x x x x x x x x
Haemolytic uraemic syndrome postmarketing — 0.3% x x x x x x x x x x x x x x x x x x x x
Venoocclusive liver disease postmarketing x x x x x x x x x
Myocardial infarction postmarketing, rare x x x x x x x x x x x x x x x x x x x
Pulmonary oedema postmarketing, uncommon x x x x x x x x x x x x x x x x x x x x
Pulmonary fibrosis postmarketing x x x x x x x x x x x x
Renal failure postmarketing, rare x x x x x x x x
Acute respiratory distress syndrome postmarketing x x x x x x x x x x x x x x x x x
Angiopathy postmarketing x x x x x x x x x x x x x x x x
Vasculitis very rare, postmarketing x x x x x x x x x x x x x x x x x
Hepatic failure postmarketing, uncommon x x x x x x x x x x x x x x
Dermatitis bullous very rare, postmarketing x x x x x x x x x x x x x x x x
Injection site reaction postmarketing, 4% x x x x x x x x x x x x x x x x
Interstitial pneumonia postmarketing, uncommon x x x x x x x x x x x x x x x x x x x
Microangiopathic haemolytic anaemia postmarketing x x x x
Tenderness rare x x x
Hepatotoxicity postmarketing, uncommon x x x x x x x x
Skin exfoliation very rare — 0% - 5% x x x x x x x x x x x x x x x x x
Capillary leak syndrome postmarketing x x x x x x x
Arrhythmia supraventricular postmarketing x x x x x
Nephropathy toxic postmarketing x x x x
Drug interaction postmarketing x x x x x
Raised liver function tests postmarketing x x x x x x x x
Respiratory failure postmarketing x x x x x x x x x x x x
Renal impairment postmarketing x
Radiation recall reaction (dermatologic) postmarketing x x x x x x x x x
Posterior reversible encephalopathy syndrome postmarketing x x x x x
Toxic epidermal necrolysis very rare x
Stevens-Johnson syndrome very rare x
Colitis ischaemic very rare x
Thrombocytosis very rare x x x
Traffic accident x x
Agranulocytosis x
Anorexia very common, 0% - 13% x x x x x x x x x x x x x x x x x x x
Bone disorder x
Breast cancer x x x x x
Chest pain x x x
Connective tissue disorder x x x
Cough x x x x x x x x x x x x x x x x x x x x
Rash 0% - 30% x x x x x x x x x x x x x x x x x x x x
Body temperature increased common — 0% - 41% x x x x x x x x x x x x x x x x x x x x
Gastrointestinal disorder x x x x
Headache very common, 0% - 7% x x x x x x x x x x x x x x x x x x x
Cardiac disorder x x x x
Haematuria postmarketing — 0% - 35% x x x x x x x x x x x x x x x x x x x x
Hypertension x x x x x x x x x x x x x x x x
Hypokalaemia x x x x x x x x
Immune system disorder x x x x
Influenza x x x x x x x x x x x x
Lymphoma x
Mediastinal disorder x x
Nervous system disorder x x x x
Oligospermia x
Pancytopenia x x x x x x x x x x x x x
Petechiae x x x x x x x x
Pleural effusion x x
Pneumonia x
Proteinuria postmarketing — 0% - 45% x x x x x x x x x x x x x x x x x x x x
Rhinitis x x x x x x x x x x x x x x x x x x x
Sweating x x x x x x x x x x x x x x x x x
Erythema x
Urinary tract disorder x x
Chills x x x x x x x x x x x x x x x x x
Hepatic function abnormal x x x x x
Peripheral sensory neuropathy x
Blood urea increased 0% - 16% x x x x x x
Injection site necrosis x x x x x x x x x x x x
Bone pain x x
Streptobacillary fever x x x x x x x x
Unspecified disorder of skin and subcutaneous tissue x x x x
Reticulocytosis x x x x x x x x
Tachypnoea x
Peripheral motor neuropathy x x x x x x x x x x x
Neurotoxicity x x x x x x x x x x x
Difficulty sleeping x x
Lung infiltration x
Hepatic enzyme increased x
Hypoxia x x
Disease progression x x
Hepatobiliary disease x x
Traumatic lung injury x
Eruption x x x x x x x x x x x x
Anaphylactoid reaction x x x x x x x x x x x x x x x x x
Tendon reflex decreased x x x
Hypoxemia x
Acute dyspnea x
Progressive renal failure x
Blood and lymphatic system disorders x x
Bilirubin normal x
Alopecia reversible x x x x
Irreversible renal failure x
Cardiotoxicity x x x
Pulmonary toxicity x x x x x x x x x x x x x x x x x
Flu symptoms x
Transaminitis x
Oral toxicity x
Hearing impaired x x x
Respiratory distress syndrome x
Metastatic disease x x

Indications

Information about indications was extracted from the indications and usage sections of the labels.

Gemcitabine

Side effects:46
Source:BC Cancer

GEMCITABINE HYDROCHLORIDE / GEMZAR

Side effects:54
Source:FDA

gemcitabine hydrochloride / GEMZAR

Side effects:67
Source:medicines.org.au

GEMCITABINE HYDROCHLORIDE / GEMZAR

Side effects:76
Source:FDA

GEMCITABINE

Side effects:77
Source:FDA Structured Product Label

gemcitabine

Side effects:77
Source:FDA Structured Product Label

gemcitabine

Side effects:78
Source:FDA Structured Product Label

GEMCITABINE

Side effects:79
Source:FDA Structured Product Label

GEMCITABINE

Side effects:79
Source:FDA Structured Product Label

gemcitabine HCl / Gemzar

Side effects:79
Source:FDA

GEMCITABINE

Side effects:81
Source:FDA Structured Product Label

GEMCITABINE

Side effects:83
Source:FDA Structured Product Label

GEMCITABINE

Side effects:84
Source:FDA Structured Product Label

GEMCITABINE

Side effects:84
Source:FDA Structured Product Label

GEMCITABINE

Side effects:84
Source:FDA Structured Product Label

Color scheme:

standard – alternative

    100%
    75%
    50%
    10%
    frequent (1% to 100%)
    infrequent (0.1% to 1%)
    rare (<0.1%)
    postmarketing
    0%
    no frequency information
    not found on label